贝塔-基-贝塔-甲基酸盐对稳定脱偿性肝硬化症的萨尔科佩尼亚的影响:试点随机对照试验
Witsarut Manasirisuk1, Jittirat Jinchai1, Jaruta Inthanon2
1Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Clinical nutrition ESPEN
|January 16, 2026
概括
在非补偿性肝硬化和肉症患者中,Beta-hydroxy-beta-methylbutyrate (HMB) 口服营养补充剂耐受性良好. 虽然没有增加肌肉质量,但HMB显示有潜力改善萨科佩尼亚指标,如相角和肌肉周长.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 营养科学 营养科学
- 老年病的医生 老年病的医生
背景情况:
- 萨尔科佩尼亚是不补偿性肝硬化患者的重要并发症.
- 在这种人群中,beta-hydroxy-beta-methylbutyrate (HMB) 补充剂对肉类的疗效尚未得到充分证实.
研究的目的:
- 为了研究含有HMB的口服营养补充剂 (ONS) 对非补偿性肝硬化和肉症患者的肌肉质量的影响.
- 评估二次结果,包括肌肉力量,质量和身体表现.
主要方法:
- 一个为期12周的随机对照试验,涉及21名患有不补偿性肝硬化和肉类的患者.
- 参与者接受了含有HMB的ONS (1.48gHMB,21g蛋白质,524kcal) 或马尔托德克斯作为对照.
- 通过生物电阻分析评估肌肉质量;还测量了肌肉力量和身体表现.
主要成果:
- 在12周后,在HMB和对照组之间没有观察到肌肉质量或手握强度的显著差异.
- 从基线来看,HMB组在相角,中臂肌肉周长和5次椅子站测试表现方面表现出了显著的组内改善.
- 含有HMB的ONS被很好地容忍,没有报告任何不良事件.
结论:
- 含有HMB的12周的ONS在不补偿性肝硬化和肉症患者中是安全的,并且耐受性良好.
- 与安慰剂相比,HMB补充剂没有显著改善肌肉质量或手握强度.
- 含有HMB的ONS对特定的与肉症相关的参数显示出潜在的益处,这需要在更大的试验中进一步调查.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...